[go: up one dir, main page]

LT3134124T - Igf-1r antikūno ir vaisto konjugatas, ir jo panaudojimas vėžio gydymui - Google Patents

Igf-1r antikūno ir vaisto konjugatas, ir jo panaudojimas vėžio gydymui

Info

Publication number
LT3134124T
LT3134124T LTEP15720045.2T LT15720045T LT3134124T LT 3134124 T LT3134124 T LT 3134124T LT 15720045 T LT15720045 T LT 15720045T LT 3134124 T LT3134124 T LT 3134124T
Authority
LT
Lithuania
Prior art keywords
igf
conjugate
antibody
cancer
drug
Prior art date
Application number
LTEP15720045.2T
Other languages
English (en)
Inventor
Ian RILATT
Michel Perez
Liliane Goetsch
Matthieu BROUSSAS
Charlotte Beau-Larvor
Jean-Francois Haeuw
Thierry Champion
Alain Robert
Original Assignee
Pierre Fabre Médicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Médicament filed Critical Pierre Fabre Médicament
Publication of LT3134124T publication Critical patent/LT3134124T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LTEP15720045.2T 2014-04-25 2015-04-27 Igf-1r antikūno ir vaisto konjugatas, ir jo panaudojimas vėžio gydymui LT3134124T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14305620 2014-04-25
PCT/EP2015/059045 WO2015162291A1 (en) 2014-04-25 2015-04-27 Igf-1r antibody-drug-conjugate and its use for the treatment of cancer

Publications (1)

Publication Number Publication Date
LT3134124T true LT3134124T (lt) 2019-05-27

Family

ID=50630736

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP15720045.2T LT3134124T (lt) 2014-04-25 2015-04-27 Igf-1r antikūno ir vaisto konjugatas, ir jo panaudojimas vėžio gydymui

Country Status (27)

Country Link
US (2) US10633448B2 (lt)
EP (2) EP3134124B1 (lt)
JP (1) JP6258523B2 (lt)
KR (1) KR101795984B1 (lt)
CN (1) CN106456800B (lt)
AU (1) AU2015250759B2 (lt)
BR (1) BR112016024619A2 (lt)
CA (1) CA2946469C (lt)
CY (1) CY1121783T1 (lt)
DK (1) DK3134124T3 (lt)
ES (1) ES2727103T3 (lt)
HR (1) HRP20190888T8 (lt)
HU (1) HUE044862T2 (lt)
IL (1) IL248455B (lt)
LT (1) LT3134124T (lt)
MA (2) MA47811A (lt)
MX (1) MX372912B (lt)
MY (1) MY186711A (lt)
PL (1) PL3134124T3 (lt)
PT (1) PT3134124T (lt)
RS (1) RS58742B1 (lt)
RU (1) RU2692563C2 (lt)
SA (1) SA516380120B1 (lt)
SI (1) SI3134124T1 (lt)
TN (1) TN2016000472A1 (lt)
UA (1) UA120364C2 (lt)
WO (1) WO2015162291A1 (lt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3134124B1 (en) * 2014-04-25 2019-02-20 Pierre Fabre Medicament Igf-1r antibody-drug-conjugate and its use for the treatment of cancer
RU2728568C2 (ru) * 2015-10-26 2020-07-30 Пьер Фабр Медикамент Композиция для лечения рака, экспрессирующего igf-1r
EP3427055A1 (en) 2016-03-07 2019-01-16 Pierre Fabre Medicament A new universal method to capture and analyze adcs for characterization of drug distribution and the drug-to-antibody ratio in biological samples
MX2021003295A (es) 2018-09-27 2021-07-16 Pf Medicament Enlazadores basados en sulfomaleimida y sus correspondientes conjugados.
CN111327570B (zh) 2018-12-14 2021-09-17 北京京东尚科信息技术有限公司 验证方法、装置和计算机可读存储介质
EP3735991A1 (fr) 2019-05-06 2020-11-11 Pierre Fabre Medicament Adc pour un traitement concomitant ou postérieur au docétaxel
MX2022012304A (es) * 2020-04-02 2022-11-30 Mersana Therapeutics Inc Conjugados de anticuerpo-farmaco que comprenden agonistas de sting.
EP3909612A1 (en) 2020-05-12 2021-11-17 Life Science Inkubator Betriebs GmbH & Co. KG Composition of nanoparticles
JP2024510435A (ja) 2021-03-18 2024-03-07 シージェン インコーポレイテッド 生体活性化合物の内部移行複合体からの選択的薬物放出
KR20250025681A (ko) * 2022-06-10 2025-02-24 아셀리린, 인크. 항-igf-1r 항체 조성물
EP4353220A1 (en) 2022-10-12 2024-04-17 Pierre Fabre Medicament Use of a liquid aqueous composition for solubilization and stabilization of an antibody-drug conjugate
WO2024180233A1 (en) 2023-03-02 2024-09-06 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts A therapeutic hpv vaccine based on validated target epitopes
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP0731106B1 (en) 1993-10-01 2004-11-17 Teikoku Hormone Mfg. Co., Ltd. Dolastatin derivatives
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
EP2286844A3 (en) * 2004-06-01 2012-08-22 Genentech, Inc. Antibody-drug conjugates and methods
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
ES2416136T3 (es) 2005-09-26 2013-07-30 Medarex, Inc. Conjugados de anticuerpo-fármaco y su uso
TW200833711A (en) 2006-12-22 2008-08-16 Genentech Inc Antibodies to insulin-like growth factor receptor
AR065803A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento
JP5290276B2 (ja) 2007-05-08 2013-09-18 ジェネンテック， インコーポレイテッド システイン改変抗ｍｕｃ１６抗体および抗体−薬物結合体
WO2009052249A1 (en) 2007-10-19 2009-04-23 Genentech, Inc. Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
EP2276509B1 (en) 2008-04-11 2016-06-15 Seattle Genetics, Inc. Detection and tratment of pancreatic, ovarian and other cancers
RU2011140491A (ru) 2009-03-06 2013-04-20 Эдженсис, Инк. Конъюгаты антитело-лекарственное средство, которые связывают белки 24р4с12
US20100316639A1 (en) * 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
MA34277B1 (fr) 2010-04-15 2013-06-01 Spirogen Developments Sarl Pyrrolobenzodiazépines et conjugués de celles-ci
CN103200950B (zh) 2010-06-10 2016-03-16 西雅图基因公司 新颖的耳他汀衍生物及其用途
US8987209B2 (en) 2010-09-29 2015-03-24 Seattle Genetics, Inc. N-carboxyalkyl-auristatin and the use thereof
ES2730941T7 (es) * 2010-10-22 2020-05-27 Seattle Genetics Inc Efectos sinérgicos entre los conjugados de conjugados anticuerpo-fármaco a base de auristatina e inhibidores de la ruta PI3K-AKT-mTOR
EP2635310A2 (en) 2010-11-05 2013-09-11 Rinat Neuroscience Corp. Engineered polypeptide conjugates and methods for making thereof using transglutaminase
CN103764667B (zh) 2011-03-16 2017-06-20 西雅图基因公司 N‑羧烷基耳他汀类及其应用
WO2012142164A1 (en) 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
ES2611359T3 (es) 2011-05-27 2017-05-08 Ambrx, Inc. Composiciones que contienen, métodos que implican y usos de derivados de dolastatina ligados con aminoácidos no naturales
KR102356286B1 (ko) 2011-05-27 2022-02-08 암브룩스, 인코포레이티드 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
CN108727466B (zh) 2012-06-07 2023-04-28 Ambrx公司 前列腺特异性膜抗原抗体药物结合物
NZ703581A (en) 2012-06-19 2016-09-30 Ambrx Inc Anti-cd70 antibody drug conjugates
WO2014008375A1 (en) 2012-07-05 2014-01-09 Mersana Therapeutics, Inc. Terminally modified polymers and conjugates thereof
JP2015526435A (ja) 2012-08-14 2015-09-10 アンジオケム インコーポレーテッド 抗体成分と血液脳関門を通過するポリペプチドと細胞毒とを含むコンジュゲート
WO2014096551A1 (en) 2012-12-21 2014-06-26 Glykos Finland Oy Linker-payload molecule conjugates
FR3005051A1 (fr) 2013-04-25 2014-10-31 Pf Medicament Derives de la dolastatine 10 et d'auristatines
EP3134124B1 (en) * 2014-04-25 2019-02-20 Pierre Fabre Medicament Igf-1r antibody-drug-conjugate and its use for the treatment of cancer
HUE047952T2 (hu) 2014-04-25 2020-05-28 Pf Medicament Ellenanyag-drog konjugátum és alkalmazása rák kezelésében történõ alkalmazásra
NZ725423A (en) * 2014-04-25 2023-07-28 Pf Medicament Igf-1r antibody and its use as addressing vehicle for the treatment of cancer
RU2728568C2 (ru) * 2015-10-26 2020-07-30 Пьер Фабр Медикамент Композиция для лечения рака, экспрессирующего igf-1r

Also Published As

Publication number Publication date
ES2727103T8 (es) 2020-03-02
SI3134124T1 (sl) 2019-06-28
WO2015162291A1 (en) 2015-10-29
PL3134124T3 (pl) 2019-09-30
MA39909B1 (fr) 2019-05-31
CN106456800B (zh) 2018-05-01
PT3134124T (pt) 2019-06-03
TN2016000472A1 (en) 2018-04-04
CY1121783T1 (el) 2020-07-31
JP6258523B2 (ja) 2018-01-10
CA2946469A1 (en) 2015-10-29
RU2016145444A3 (lt) 2018-11-22
RU2692563C2 (ru) 2019-06-25
BR112016024619A2 (pt) 2017-10-10
KR101795984B1 (ko) 2017-11-10
MX372912B (es) 2025-03-04
US20200270352A1 (en) 2020-08-27
CA2946469C (en) 2019-10-29
RU2016145444A (ru) 2018-05-28
KR20160146817A (ko) 2016-12-21
MA39909A (fr) 2017-03-01
JP2017513900A (ja) 2017-06-01
EP3498301A1 (en) 2019-06-19
US11661457B2 (en) 2023-05-30
MX2016013704A (es) 2017-03-31
MY186711A (en) 2021-08-12
US20170043031A1 (en) 2017-02-16
UA120364C2 (uk) 2019-11-25
EP3134124B1 (en) 2019-02-20
EP3134124A1 (en) 2017-03-01
HRP20190888T1 (hr) 2019-07-12
AU2015250759A1 (en) 2016-11-10
MA47811A (fr) 2019-06-19
HUE044862T2 (hu) 2019-11-28
ES2727103T3 (es) 2019-10-14
HRP20190888T8 (hr) 2019-10-04
IL248455B (en) 2020-01-30
IL248455A0 (en) 2016-11-30
RS58742B1 (sr) 2019-06-28
DK3134124T3 (da) 2019-05-06
CN106456800A (zh) 2017-02-22
SA516380120B1 (ar) 2019-02-27
AU2015250759B2 (en) 2017-11-30
US10633448B2 (en) 2020-04-28

Similar Documents

Publication Publication Date Title
HRP20190888T8 (hr) Konjugat antitijela za igf-1r i lijeka i njegova upotreba u liječenju karcinoma
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
IL249065A0 (en) Combination of treatments for cancer treatment
LT3122358T (lt) Egfr ir cmet inhibitorių deriniai, skirti vėžio gydymui
IL276733A (en) Use of Aribolin in cancer treatment
IL259996A (en) Combinations for cancer treatment
IL248767B (en) Trimethoxyphenyl-benzaimidazole compounds for cancer treatment
IL251905B (en) Epilimod for use in the treatment of kidney cancer
SG11201701035SA (en) Cancer diagnosis and therapy
HK1231561A1 (zh) 癌症治療
IL251903B (en) Epilimod for use in the treatment of colon cancer
IL250507A0 (en) Anti-ck8 antibodies for use in cancer therapy
GB201408297D0 (en) Treatment of cancer
EP3151821A4 (en) Marmelin analogs and methods of use in cancer treatment
GB201407837D0 (en) Methods of cancer therapy
GB201417456D0 (en) Treatment of cancer
GB201410695D0 (en) Uses of oligouronates in cancer treatment
GB201418640D0 (en) Agents and methods for treatment of cancer
GB201409362D0 (en) Treatment of cancer
GB201405449D0 (en) Treatment of cancer
GB201405075D0 (en) Treatment of cancer